CB2 receptors hold key to overcoming breast cancer drug resistance

This groundbreaking study reveals an unexpected connection between the cannabinoid CB2 receptor (CB2R) and resistance to trastuzumab, a leading HER2-targeted therapy for breast cancer. Researchers found that cancer cells with lower CB2R expression are more likely to develop resistance to this life-saving drug. In clinical samples, patients whose tumors showed decreased CB2R expression after treatment had poorer long-term outcomes, suggesting CB2R levels could serve as a valuable predictor of treatment success.

The research demonstrates a sophisticated molecular mechanism: when CB2R is lost or downregulated in cancer cells, they escape the immune system's natural defenses (specifically interferon-gamma signaling) and switch their dependency from HER2 to EGFR pathways. This shift allows cancer cells to survive trastuzumab treatment by relying on alternative survival signals. The team discovered that combining EGFR inhibitors with trastuzumab restored drug sensitivity, offering a potential therapeutic strategy to overcome resistance.

The implications extend beyond traditional oncology. This study positions the endocannabinoid system as a critical player in cancer cell survival and drug resistance, opening new avenues for treatment. The researchers propose dual HER2/EGFR targeting and cannabinoid-based therapies as potential strategies to enhance treatment outcomes. These findings suggest that understanding how cannabinoid signaling influences cancer biology could lead to improved therapies for HER2-positive breast cancer patients who currently lack effective treatment options.